TherVacB - A Multi-center Phase 1b/2a Trial to Assess Safety, Tolerability and Immunogenicity of a Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; MVA HBV (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms TherVacB
- 10 Apr 2025 Planned initiation date changed from 1 Dec 2024 to 1 May 2025.
- 06 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Dec 2024.
- 25 Jul 2024 New trial record